Episode
Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov
- Podcast
- Hematologic Oncology Update
- Published
- Sep 23, 2026
- Duration seconds
- 2981
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hematologic-oncology-update-916423/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26) Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36) Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48) Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00) Prevention and management of ophthalmic events related to treatment with belamaf (21:27) Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49) Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27) Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53) CME information and select publications